1995 - The Company was incorporated as Cadila Healthcare Private Ltd. on May 15, under the company act, 1956 and subsequently the Company was converted into a public company and then renamed as Cadila Healthcare Ltd. effective from Juy 17, 1996. - The name "Cadila" shall be used only for "Cadila Healthcare Limited" (Zydus Cadila), "Cadila Pharmaceuticals Limited" (CPL) and "Cadila Laboratories Limited" (CLL). - The Company is flagship company of Zydus Cadila Group. - The Company's operations include pharmaceuticals (human formulations, veterinary formulations and bulk drugs); diagnostics, herbal products, skin care products and other OTC products. - The Company has 6 subsidiaries Indon Healthcare Ltd., Zydus Pharmaceuticals Ltd., Zudus Aqrovet Ltd., Zoom Properties Pvt. Ltd., Zydus International Pvt. Ltd., Ireland and Zydus Healthcare S.A. (Pvt) Ltd., South Africa. - Zydus Cadila signed an agreement with Anda Biologicals, France, for Marketing and distribution of diagnostic kits. Anda to appoint a max. of two distributors in India. 1996 - Zydus Cadila signed an agreement with Centeon L.L.C., USA and Centeon Pharama GMBH, Germany for Exclusive rights to sell and distribute plasma products in India and Nepal. - In May, Zydus Cadila signed an agreement with Acta Services Srl., Rome for distribution of Diagnostic instrument Acto 1 Analyser manu. By Acta. - In June, Zydus Cadila signed an agreement with China Resources Gulin Pharma, Works, China, for exclusive supply of Artesunate Granules to Zydus Cadila. - In July, Zydus Cadila signed an agreement with Shimizu Chemical Corporation, Japan, for Marketing of specified products by Zydus Cadila in India. 1997 - A Scheme of Arrangement and Amalgamation was sanctioned by honorable High Court of Gujarat by order passed on May 2 issued on August 16th. - Zydus Cadila would issued 1,48,423 fully paid-up equity shares of Rs 10/- each to the shareholders of Patel Group in exchange for the assets transferred to them of Transferor companies. - Zydus Cadila has also tied-up with Regional Research Laboratory Jammu, to develop Enzymatic Resolution for Paroxetine HCL and some other Enzymatic products. 1998 - In February, Zydus Cadila signed an agreement with Apotex SA Pty. Ltd. for manufacturer of Amoxycillin, Ampicillin, Co - trimoxazole, paracetamol. - Zydus Cadila has also entered into a joint venture with Korea Green Cross Corporation, Korea, to manufacture and market recombinant Hepatitis B vaccine in India. 1999 - In April, Zydus Cadila signed an agreement with Ethical Holdings Plc, Beta Pharma, and Ethical Pharma South America S.A. for Know-how Licence Agreement to manufacture, marketing and sell transdermal pharmaceutical formulations. - In September, Zydus Cadila signed an agreement with Cherry Valley Farms Ltd., UK for supply of vaccine eggs. - Zydus Cadila has entered into a 50:50 joint venture with Byk Gulden of Germany, a renowned, research-oriented Pharma company of Germany and the world-wide patent holder of the novel proton pump inhibitor, "Pantoprazole". - During the year under report, the Company had issued 2,00,000 12% Cumulative Redeemable Preference shares of Rs. 100/- each fully paid to the members of the Company, which are redeemable at par on 1st July, 2001. - During the year under report, Indon Healthcare Limited and Zydus Aqrovet Limited, have become wholly owned subsidiaries of the company. - During the year under report, the Company has undertaken to set up a new project for manufacturing the bulk drug-Losartan at Ankleshwar. - The Company laid the foundation for a new feed supplement plant, at Vatwa. The feed supplement for poultry and cattle has been developed by tie company's R & D bio-tech department. - The Company has set up a joint venture company to manufacture the break-through molecule Pantoprazole. The Company is also undertaking discovery research projects with Byk Gulden as a pan of the Joint Venture. - The Company has entered into a technical-cum-marketing tie-up with the Swiss Serum and Vaccine Institute, Berne, Institute to launch a range of vaccines in India. - The Company has entered into a joint venture with the Haffkine institute to undertake research in the field of human vaccine and equine sera. - A new State-of-Art Research & Development centre being set-up with the capital cost of approximately Rs. 25.00 crores in the Village: Moraiya. Taluka:Sanand, Dist.: Ahmedabad. - During the year under report the Company has launched several new products in the market : Vac Typh, HB Vac, Xylodac, Losartan, Losacar was the first to be launched in India & Matergam P. - The Company has set up manufacturing premises to manufacture the feed supplement - Improval at GIDC Vatwa. - Shir Pranlal Bhogilal was appointed as an additional Director of the Company with effect from 15th December, 1998 pursuant to Section 260 of the Companies Act, 1956. - Shri Mukesh M. Patel Director of the Company retires by rotation and he is eligible for reappointment. - A new welfare policy has been introduced for employees of the Company. 2000 - The Company is setting up wholly owned subsidiaries abroad and plans to acquire overseas companies to market products. - The Company has entered into License Agreement for phased manufacture and technical know-how transfer with Swiss Serum and Vaccine Institute, Switzerland for the manufacture of Purified Cuck Embroy Vaccine. - The Country's fifth largest pharmaceutical company, is considering offering stocks to its employees through an employees' stock option scheme. - The Company has launched two drugs for the treatment of human immunodeficiency virus. - The Bulk Drugs at Ankleshwar in Gujarat has an ISO 9002 certification for the manufacture and supply of a number of molecules. - Public Issue of 1,48,86,000 No. of Equity shares ("Issue") of Rs 5/- each issued for cash at a premium of Rs [] per share aggregating Rs [] million. The Issue includes a Book Built Portion of 1,33,97,400 No. of equity shares and a Fixed price portion of 14,88,600 No. of Equity Shares. - Authorised share capital of the Company is Rs 500 million divided into 9,00,00,000 No. of Equity Shares of Rs 5/- each and 5,00,000 Preference Shares of Rs 100/- each. - During the year under report, the Company has been recognise as a "Prestigious Unit" and granted adhoc eligibility for Sales Tax deferment by the Industries Commissionerate, Gandhinagar, under New Incentive Policy - Capital Investment Incentive to Premier/ Prestigious unit scheme 1995-2000. - During the year under report Zydus Pharmaceuticals Limited and Zoom Properties Limited have become Wholly Owned Subsidiaries of the Company. - The Company has formed a JV Company in the name of Zydus Byk Healthcare Limited with an equal participation in collaboration with Byk Gulden Lomberg Chemische Fabrik GmbH, Germany, for manufacturing of Bulk Drugs, Formulations and R & D. - The Company has also formed a JV Company in the name of Sarabhai Zydus Animal Health Ltd. in collaboration with Ambalal Sarabhai Enterprises Ltd., Baroda, with an equal participation to carry on the business of animal health segments. - The company has also entered into a technical collaboration with Ethical Holdings of U.K. to manufacture and market transdermal patches in India. - The Company launched block-buster molecules Atorvastatin (Atorva), Lamivudine (Lamidac 100) and Celecoxib (Zycel), Meloxicam (Mel-OD) and Carvedilol (Carvil) during the year. - The company was the first to launch the anti-hypertensive drug Losartan in India. - Currently ranked 6th largest pharmaceutical company in India, Cadila Healthcare is one of the fastest growing pharmaceutical companies in the country. - It has also entered into a technical collaboration with Ethical Holdings of the UK to manufacture and market transdermal patches in India. - Zydus Cadilla has also entered into a technical collaboration with Ethical Holdings of the UK to manufacture and market transdermal patches in India. - Cadlia Healthcare (CHL) has signed an MoU with Rs 54 crore Recon Limited, whereby it will acquire all the 8 formulation brands of the Bangalore based comapny, as well as its distribution network. - The new company, `Recon Healthcare Ltd' is now a subsidiary of Zydus Cadila with Zydus holding 90 per cent stake. - Cadila Healthcare Ltd is setting up wholly owned subsidiaries abroad and plans to acquire overseas companies to market products. - Cadila also launched zidovudine, which is imported and marketed under the brand name Zydowin. Zidovudine, commonly called AZT, is an AIDS-retardant drug made by Glaxo Wellcome. - Zydus Alidac, the marketing arm of Cadila Healthcare Ltd., has launched www.penegra.org. -The Ahmedabad-based Cadoila Healthcare has completed the phase-III clinical trials and the bioequivalence study of the wonder drug sildenafil citrate (Viagra). 2001 - Cadila Healthcare has signed a three year collaborative R&D agreement with Danish biotech company Pantheco in the field of anti-bacterials. - The neurosciences division launched by the company has introduced anxiolytic paroxetine for the first time in the country. - Cadila Healthcare Ltd has posted a 14.75 per cent increase in net profit at Rs 21.86 crore for the quarter ended September 30, 2001.YEAR EVENTS 1995 - The Company was incorporated as Cadila Healthcare Private Ltd. on May 15, under the company act, 1956 and subsequently the Company was converted into a public company and then renamed as Cadila Healthcare Ltd. effective from Juy 17, 1996. - The name "Cadila" shall be used only for "Cadila Healthcare Limited" (Zydus Cadila), "Cadila Pharmaceuticals Limited" (CPL) and "Cadila Laboratories Limited" (CLL). - The Company is flagship company of Zydus Cadila Group. - The Company's operations include pharmaceuticals (human formulations, veterinary formulations and bulk drugs); diagnostics, herbal products, skin care products and other OTC products. - The Company has 6 subsidiaries Indon Healthcare Ltd., Zydus Pharmaceuticals Ltd., Zudus Aqrovet Ltd., Zoom Properties Pvt. Ltd., Zydus International Pvt. Ltd., Ireland and Zydus Healthcare S.A. (Pvt) Ltd., South Africa. - Zydus Cadila signed an agreement with Anda Biologicals, France, for Marketing and distribution of diagnostic kits. Anda to appoint a max. of two distributors in India. 1996 - Zydus Cadila signed an agreement with Centeon L.L.C., USA and Centeon Pharama GMBH, Germany for Exclusive rights to sell and distribute plasma products in India and Nepal. - In May, Zydus Cadila signed an agreement with Acta Services Srl., Rome for distribution of Diagnostic instrument Acto 1 Analyser manu. By Acta. - In June, Zydus Cadila signed an agreement with China Resources Gulin Pharma, Works, China, for exclusive supply of Artesunate Granules to Zydus Cadila. - In July, Zydus Cadila signed an agreement with Shimizu Chemical Corporation, Japan, for Marketing of specified products by Zydus Cadila in India. 1997 - A Scheme of Arrangement and Amalgamation was sanctioned by honorable High Court of Gujarat by order passed on May 2 issued on August 16th. - Zydus Cadila would issued 1,48,423 fully paid-up equity shares of Rs 10/- each to the shareholders of Patel Group in exchange for the assets transferred to them of Transferor companies. - Zydus Cadila has also tied-up with Regional Research Laboratory Jammu, to develop Enzymatic Resolution for Paroxetine HCL and some other Enzymatic products. 1998 - In February, Zydus Cadila signed an agreement with Apotex SA Pty. Ltd. for manufacturer of Amoxycillin, Ampicillin, Co - trimoxazole, paracetamol. - Zydus Cadila has also entered into a joint venture with Korea Green Cross Corporation, Korea, to manufacture and market recombinant Hepatitis B vaccine in India. 1999 - In April, Zydus Cadila signed an agreement with Ethical Holdings Plc, Beta Pharma, and Ethical Pharma South America S.A. for Know-how Licence Agreement to manufacture, marketing and sell transdermal pharmaceutical formulations. - In September, Zydus Cadila signed an agreement with Cherry Valley Farms Ltd., UK for supply of vaccine eggs. - Zydus Cadila has entered into a 50:50 joint venture with Byk Gulden of Germany, a renowned, research-oriented Pharma company of Germany and the world-wide patent holder of the novel proton pump inhibitor, "Pantoprazole". - During the year under report, the Company had issued 2,00,000 12% Cumulative Redeemable Preference shares of Rs. 100/- each fully paid to the members of the Company, which are redeemable at par on 1st July, 2001. - During the year under report, Indon Healthcare Limited and Zydus Aqrovet Limited, have become wholly owned subsidiaries of the company. - During the year under report, the Company has undertaken to set up a new project for manufacturing the bulk drug-Losartan at Ankleshwar. - The Company laid the foundation for a new feed supplement plant, at Vatwa. The feed supplement for poultry and cattle has been developed by tie company's R & D bio-tech department. - The Company has set up a joint venture company to manufacture the break-through molecule Pantoprazole. The Company is also undertaking discovery research projects with Byk Gulden as a pan of the Joint Venture. - The Company has entered into a technical-cum-marketing tie-up with the Swiss Serum and Vaccine Institute, Berne, Institute to launch a range of vaccines in India. - The Company has entered into a joint venture with the Haffkine institute to undertake research in the field of human vaccine and equine sera. - A new State-of-Art Research & Development centre being set-up with the capital cost of approximately Rs. 25.00 crores in the Village: Moraiya. Taluka:Sanand, Dist.: Ahmedabad. - During the year under report the Company has launched several new products in the market : Vac Typh, HB Vac, Xylodac, Losartan, Losacar was the first to be launched in India & Matergam P. - The Company has set up manufacturing premises to manufacture the feed supplement - Improval at GIDC Vatwa. - Shir Pranlal Bhogilal was appointed as an additional Director of the Company with effect from 15th December, 1998 pursuant to Section 260 of the Companies Act, 1956. - Shri Mukesh M. Patel Director of the Company retires by rotation and he is eligible for reappointment. - A new welfare policy has been introduced for employees of the Company. 2000 - The Company is setting up wholly owned subsidiaries abroad and plans to acquire overseas companies to market products. - The Company has entered into License Agreement for phased manufacture and technical know-how transfer with Swiss Serum and Vaccine Institute, Switzerland for the manufacture of Purified Cuck Embroy Vaccine. - The Country's fifth largest pharmaceutical company, is considering offering stocks to its employees through an employees' stock option scheme. - The Company has launched two drugs for the treatment of human immunodeficiency virus. - The Bulk Drugs at Ankleshwar in Gujarat has an ISO 9002 certification for the manufacture and supply of a number of molecules. - Public Issue of 1,48,86,000 No. of Equity shares ("Issue") of Rs 5/- each issued for cash at a premium of Rs [] per share aggregating Rs [] million. The Issue includes a Book Built Portion of 1,33,97,400 No. of equity shares and a Fixed price portion of 14,88,600 No. of Equity Shares. - Authorised share capital of the Company is Rs 500 million divided into 9,00,00,000 No. of Equity Shares of Rs 5/- each and 5,00,000 Preference Shares of Rs 100/- each. - During the year under report, the Company has been recognise as a "Prestigious Unit" and granted adhoc eligibility for Sales Tax deferment by the Industries Commissionerate, Gandhinagar, under New Incentive Policy - Capital Investment Incentive to Premier/ Prestigious unit scheme 1995-2000. - During the year under report Zydus Pharmaceuticals Limited and Zoom Properties Limited have become Wholly Owned Subsidiaries of the Company. - The Company has formed a JV Company in the name of Zydus Byk Healthcare Limited with an equal participation in collaboration with Byk Gulden Lomberg Chemische Fabrik GmbH, Germany, for manufacturing of Bulk Drugs, Formulations and R & D. - The Company has also formed a JV Company in the name of Sarabhai Zydus Animal Health Ltd. in collaboration with Ambalal Sarabhai Enterprises Ltd., Baroda, with an equal participation to carry on the business of animal health segments. - The company has also entered into a technical collaboration with Ethical Holdings of U.K. to manufacture and market transdermal patches in India. - The Company launched block-buster molecules Atorvastatin (Atorva), Lamivudine (Lamidac 100) and Celecoxib (Zycel), Meloxicam (Mel-OD) and Carvedilol (Carvil) during the year. - The company was the first to launch the anti-hypertensive drug Losartan in India. - Currently ranked 6th largest pharmaceutical company in India, Cadila Healthcare is one of the fastest growing pharmaceutical companies in the country. - It has also entered into a technical collaboration with Ethical Holdings of the UK to manufacture and market transdermal patches in India. - Zydus Cadilla has also entered into a technical collaboration with Ethical Holdings of the UK to manufacture and market transdermal patches in India. - Cadlia Healthcare (CHL) has signed an MoU with Rs 54 crore Recon Limited, whereby it will acquire all the 8 formulation brands of the Bangalore based comapny, as well as its distribution network. - The new company, `Recon Healthcare Ltd' is now a subsidiary of Zydus Cadila with Zydus holding 90 per cent stake. - Cadila Healthcare Ltd is setting up wholly owned subsidiaries abroad and plans to acquire overseas companies to market products. - Cadila also launched zidovudine, which is imported and marketed under the brand name Zydowin. Zidovudine, commonly called AZT, is an AIDS-retardant drug made by Glaxo Wellcome. - Zydus Alidac, the marketing arm of Cadila Healthcare Ltd., has launched www.penegra.org. -The Ahmedabad-based Cadoila Healthcare has completed the phase-III clinical trials and the bioequivalence study of the wonder drug sildenafil citrate (Viagra). 2001 - Cadila Healthcare has signed a three year collaborative R&D agreement with Danish biotech company Pantheco in the field of anti-bacterials. - The neurosciences division launched by the company has introduced anxiolytic paroxetine for the first time in the country. - Cadila Healthcare Ltd has posted a 14.75 per cent increase in net profit at Rs 21.86 crore for the quarter ended September 30, 2001. 2002 -Cadila Healthcare Ltd has informed BSE that at the meeting of the Board of Directors of the company held on August 20, 2002 it has been decided to issue/allot Secured Redeemable Non Convertible Debentures for an aggregate face value of Rs 700 million by private placement basis at an interest rate of 8.40% p.a. 2003 -Mr.UpenShah has been designated as the Company Secretary and Compliance Officer of Cadila Healthcare Ltd. -Zydus Cadila, the ahmedabad based healthcare has bagged global marketing rights of an anti-rabies vaccine of vaxirab a swiss company Berna Biotech. -Cadila Healthcare receives Mumbai High court approval for the scheme of amalgamation with German Remedies Ltd and Zoom Properties Ltd. -Cadila Healthcare Ltd has acquired US base Alpharma Inc's French Subsidiary Alpharma SAS France for a consideration of Euro 5.5 million. -Mr.H.K.Bilpodiwala, Mr.H.Dhanarajgir and Mr.A.S Diwanji have been appointed as the additional directors on the board of the company. -Zydus Cadila Healthcare Ltd has signed a pact with Schering AG, Germany which allows the Indian Pharmaceuticals major to market Schering's patented products in India. -Duphar Interfran, a subsidiary of Fermenta Biotech Ltd signed an agreement with Cadila Ltd for the sale of FBL's global patents of Chiral Building blocks and process teechnology for the manufacture of Lisinopril and Benazepril. -Zydus forges marketing pact with Schering 2004 -Zydus Cadila sets up Zydus Pharmaceuticals USA, Inc -Zydus Cadila inks strategic pact with Boehringer Ingelheim -Zyndus Altana Healthcare - the JV between Altana Pharma AG and Zyndus Cadila, has been accredited with the ISO 9001-2000 certificate. 2005 - Zydus Cadila receives approval from the USFDA to market the anti-hypertensive drug, Atenolol, and an anti-infective drug, Clindamycin on 31 Jan and 1 Feb. -Zydus Cadila unveils 'Pitavastatin' to control cholesterol on February 21, 2005 -Cadila ties up with Tyco unit to sell generic drugs in US - Launches NuPatch - India's first indigenously manufactured Diclofenac transdermal patch for pain relief. -Cadila Healthcare & Mayne signs agreement to set up JVC to manufacture specialty oncology products -Cadila Healthcare - German Remedies launches Fludara Oral for Lymphocytic Leukaemia -Zydus Cadila receives tentative approval for Divalproex Sodium DR Tablets from US FDA -Cadila Healthcare receives approval for Promethazine Tablets from USFDA -Cadila Healthcare enters into JV with BSVL 2006 -Zydus Cadila forges alliance with French firm -Zydus Cadila receives USFDA approval for Simvastatin Tablets -Zydus Cadila to acquire Nutralite - India's largest selling cholesterol-free margarine -Sarabhai Zydus to roll out immuno-diagnostics kits -Cadila Healthcare has given the Bonus in the Ratio of 1:1 2007 -Cadila Healthcare Ltd on April 19, 2007 has announced the acquisition of Nippon Universal Pharmaceutical Ltd. - Cadila Healthcare Ltd has announced that its second overseas acquisition this year, the Company signed an agreement to acquire 100% stake in Quimica e Farmaceutica Nikkho do Brasil Ltda. -Zydus Cadila acquires Nippon Universal, strengthens its presence in Japan -Zydus Cadila, the first to launch revolutionary anti-obesity drug Slimona in India -Zydus Cadila acquires Brazilian Company Nikkho 2008 -Zylus Cadila, Karo Bio to jointly develop new drugs -Zydus Cadila & Karo Bio of Sweden sign research agreement for a novel drug to treat inflammatory diseases -Zydus Cadila acquires Etna Biotech, a subsidiary of Crucell N.V. -Zydus scores with first day launch of Venlafaxine Hydrochloride in the US 2009 -Zydus Cadila announces research collaboration to discover and develop new cardiovascular medicines -Zydus Research Centre Receives AAALAC Accreditation 2010 -CHL announces Bonus Shares in the ratio of 1:2 - India unveiled its first indigenous H1N1 vaccine, which was developed by drug firm Cadila Healthcare and this vaccine will provide immunity from the H1N1 virus strain for one year. 2011 -Company has signed an Agreement with Bayer HealthCare to set up 50:50 Joint Venture Company in the name of "Bayer Zydus Pharma -Cadila gets USFDA nod for diabetes drug trial -Cadila Health acquires Bremer Pharma from ICICI Venture 2012 -"Cadila Healthcare enters into a settlement and license agreement with Somaxon for Silenor" -Cadila Healthcare gets USFDA nod for Aripiprazole orally disintegrating tablets 2013 -Zydus Cadila receives tentative approval for Doxepin Hcl tablets -Zydus and IDRI sign agreement for the development of IDRI's Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar) -Zydus and Pieris Sign Broad Co-Development Alliance for Novel Anticalinr Therapeutics -Zydus Pharmaceuticals (USA) Inc agreement with Warner Chilcott Company LLC 2014 -Zydus and gilead enter into a generic licensing agreement to manufacture breakthrough treatment for hepatitis c -Zydus launches world's first biosimilar of Adalimumab -Cadila Healthcar - Lipaglyn - India's first NCE launched in the market -Zydus and IDRI sign agreement for the development of IDRI's -Zydus and Pieris Sign Broad Co-Development Alliance for Novel 2015 -Zydus Cadila has completed the single ascending dose (SAD) range -Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences -Cadila Healthcare Ltd has purchased the remaining 50 per cent shares of its joint venture firm, Zydus BSV Pharma Pvt Ltd (Zydus BSV) -Cadila Healthcare Ltd has received the final approval from USFDA for Pyridostigmine Bromide Tablets -Cadila Healthcare Ltd has received the market authorisation from the United States Food and Drug Administration to market drug for the treatment of chronic pain or cancer related pain. -Cadila Healthcare Ltd has received final approval from the USFDA to market Amiloride Hydrochloride Tablets USP, 5 mg -Zydus launches 'Tenglyn', the most affordable gliptin for diabetics in India -Cadila Healthcare has splits its face value from Rs. 5 to Rs. 1 2016 -Zydus Cadila acquires select animal health brands of Zoetis -Cadila Healthcar - Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP -Cadila Healthcar - Zydus acquires the gastro therapy 'Actibile' from Albert David Limited -Zydus gets USFDA approval for Glyburide Tablets -Cadila Healthcar - Zydus acquires two ANDAs from Teva, strengthens its US portfolio -Cadila Healthcar - Zydus acquires six brands from MSD 2017 -Zydus receives final approval from the USFDA for Temozolomide Capsules and Nadolol Tablets USP. - 'Zydus Cadila acquires Sentynl Therapeutics Inc., a US based specialty pharmaceutical company'. -Zydus and Pharm Aid Ltd., enter into an exclusive agreement for vaccine technology in Russia. -Zydus receives EIR Report for Manufacturing Facility at the Pharma SEZ at Ahmedabad. -Zydus receives final approval from the USFDA for Desvenlafaxine Extended-Release Tablets. -Cadila Healthcare enters into agreement with Phibro Animal Health Corporation to license Phibro innovative poultry vaccine technologies and know-how to a new vaccine manufacturing facility to be built by Zydus Cadila to serve the fast growing poultry market in India. 2018 -Zydus Cadila gets USFDA nod for sedative injection. -Zydus enters into agreement with Medicure International to commercialize New Drug Application (NDA) product, pitavastatin magnesium (ZYPITAMAG TM ) in the United States. -Zydus Cadila bags approval from the USFDA to market Omeprazole and Sodium Bicarbonate Capsules 20 mg/1100 mg (OTC). -Zydus Cadila bags approval for Carbidopa Tablets. -CSIR-IMTECH inks pact with Zydus Cadila. -Zydus Cadila launches generic erectile dysfunction drug in US. 2019 -Zydus launches Ramelteon Tablets for treatment of insomnia. -Zydus receives tentative USFDA approval for Lorcaserin Hydrochloride Tablets used in the treatment of obesity. 2020 -Zydus & CMS enter pact for Desidustat in Greater China. -Zydus Wellness launches hand sanitizer under Nycil brand to meet growing demand. -Zydus Cadila launches COVID-19 drug Remdesivir in India. -Zydus Cadila launches new product for COPD patients in India. 2021 -Zydus Cadila launches Trastuzumab Emtansine under brand name Ujvira. -Cadila Healthcare receives orphan drug designation for malaria treatment compound. 2022 -Zydus Life gets USFDA final approvals for Silodosin, Pregabalin. -Zydus Group had 338 approvals and filed over 431 ANDAs since the commencement of the filing process -Zydus Life gets final USFDA approval for Topiramate extended-release capsules. -Zydus Lifesciences' arm gets EC nod for MoCD injection. -Pharma Company Of The Year Award by ETHealthworld India Pharmaworld Awards 2022. -Excellence In CSR at ETHealthworld India Pharmaworld Awards 2022. -7th India Pharma and India Medical Device award by the Government of India, Department of Pharmaceuticals in the India Pharma CSR of the year category. 2023 -Zydus Lifesciences inks licensing pact with Daewoong Pharmaceutical. -Zydus Lifesciences receives USFDA approval for Acyclovir Cream. -""Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics"". -Zydus lifesciences limited received 7th CSR Health Impact Award under CSR Health Project (Large Corporate) 2023 by IHW Council for our Healthcare Project in aspiration district. 2024 -Zydus Lifesciences gets WHO prequalification for Typhoid Vi conjugate vaccine. - Zydus Lifesciences gets Mexican regulatory nod for cancer treatment biosimilar.